| Literature DB >> 30248673 |
Eric Baudin1, Aimee R Hayes2, Jean-Yves Scoazec3, Pier Luigi Filosso4, Eric Lim5, Gregory Kaltsas6, Andrea Frilling7, Jie Chen8, Beata Kos-Kudła9, Vera Gorbunova10, Bertram Wiedenmann11, Els Nieveen van Dijkum12, Jaroslaw B Ćwikła13, Jenny Falkerby14, Juan W Valle15, Matthew H Kulke16, Martyn E Caplin17.
Abstract
Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.Entities:
Keywords: Bronchial carcinoid tumours; NET; Neuroendocrine neoplasms; Pulmonary carcinoids
Year: 2018 PMID: 30248673 DOI: 10.1159/000493980
Source DB: PubMed Journal: Neuroendocrinology ISSN: 0028-3835 Impact factor: 4.914